Current Oncology (Feb 2023)

The Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Patients with Metastatic Renal Cell Carcinoma

  • Andreea Ioana Parosanu,
  • Cristina Florina Pirlog,
  • Cristina Orlov Slavu,
  • Ioana Miruna Stanciu,
  • Horia-Teodor Cotan,
  • Radu Constantin Vrabie,
  • Ana-Maria Popa,
  • Mihaela Olaru,
  • Cristian Iaciu,
  • Lucian Ioan Bratu,
  • Ionut Florian Baicoianu,
  • Oana Moldoveanu,
  • Catalin Baston,
  • Cornelia Nițipir

DOI
https://doi.org/10.3390/curroncol30020187
Journal volume & issue
Vol. 30, no. 2
pp. 2457 – 2464

Abstract

Read online

Background: Metastatic renal cell carcinoma (mRCC) is an aggressive cancer characterised by an increased recurrence rate and an inadequate response to treatment. This study aimed to investigate the importance of the neutrophil-to-lymphocyte ratio (NLR) as a prognostic marker for long-term survival in patients with mRCC. Methods: We retrospectively analysed data from 74 patients with mRCC treated at our medical centre with tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs). We evaluated the predictive value of NLR for overall survival (OS) in these patients. Results: The median OS was 5.1 months in the higher NLR group (≥3) and 13.3 months in the lower NLR group (p p = 0.411) or in the high NLR group (4.7 vs. 5.5 months, p = 0.32). Both univariate and multivariate analyses revealed that a higher NLR was an independent prognostic factor of long-term survival in patients with mRCC treated with first-line therapy. Conclusions: This retrospective study showed that adding NLR to other Memorial Sloan Kettering Cancer Center (MSKCC) and International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) variables might improve the prognostic and predictive power of these models.

Keywords